Inovio Pharmaceuticals, Inc. (INO)
| Previous close | 8.80 |
| Open | 8.77 |
| Bid | 8.70 x 1400 |
| Ask | 8.71 x 2200 |
| Day's range | 8.64 - 8.89 |
| 52-week range | 6.88 - 33.79 |
| Volume | 4,780,611 |
| Avg. volume | 14,536,677 |
| Market cap | 1.816B |
| Beta (5Y monthly) | 0.76 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.07 |
| Earnings date | 01 Mar 2021 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 15.63 |
- Business Wire
INOVIO INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Inovio Pharmaceuticals Inc. - INO
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF continues its investigation into Inovio Pharmaceuticals Inc. (NasdaqGS: INO).
- Motley Fool
This 1 Element May Be Holding Inovio's Vaccine Back
In this Motley Fool Live video recorded on March 26, healthcare and cannabis bureau chief Corinne Cardina and Fool.com contributor Adria Cimino discuss why Inovio Pharmaceuticals' (NASDAQ: INO) technology may result in a longer timeline to commercialization. Corinne Cardina: I have a question for you about the Inovio device. Do you think that this delivery device puts Inovio at a disadvantage compared to vaccines that do not require a device?
- Motley Fool
Vaxart or Inovio: Which Is More Likely to Double Your Money?
There are many ways to examine a stock's potential. Players predict which stocks will outperform or underperform the S&P 500 over a particular time frame. It also rates each stock according to the number of players who say it will beat the S&P 500.
